Download ORGANIC CHEMISTRY SEMINAR Professor Jeff Kelly Biological and Chemical Approaches to Adapt

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Prion wikipedia , lookup

Signal transduction wikipedia , lookup

Hedgehog signaling pathway wikipedia , lookup

Proteasome wikipedia , lookup

Phosphorylation wikipedia , lookup

Magnesium transporter wikipedia , lookup

Protein wikipedia , lookup

List of types of proteins wikipedia , lookup

G protein–coupled receptor wikipedia , lookup

Protein design wikipedia , lookup

Protein structure prediction wikipedia , lookup

Protein moonlighting wikipedia , lookup

Protein (nutrient) wikipedia , lookup

Protein phosphorylation wikipedia , lookup

Protein folding wikipedia , lookup

Nuclear magnetic resonance spectroscopy of proteins wikipedia , lookup

Protein–protein interaction wikipedia , lookup

Proteolysis wikipedia , lookup

Transcript
ORGANIC CHEMISTRY SEMINAR
Professor Jeff Kelly
Scripps Research Institute
Biological and Chemical Approaches to Adapt
Proteostasis to Ameliorate Protein Aggregation Diseases
The cellular protein homeostasis, or proteostasis network, regulates
proteome function by controlling ribosomal protein synthesis, chaperone and
enzyme mediated protein folding, protein trafficking, proteindegradation and
the like. Stress responsive signaling pathways match proteostasis network
capacity with demand in each subcellular compartment to maintain cellular
homeostasis. The beginning of the seminar will focus on how the
proteostasis network can be adapted through unfolded protein response
arm-selective signaling to alleviate gain-of-toxic-function diseases where
excessive secretion of misfolding and aggregation of proteins leads to the
amyloid diseases. The second part of the seminar will focus on a chemical
strategy to achieve protein homeostasis, wherein small molecule kinetic
stabilizers produced by structure-based drug design are employed to halt
the progression of peripheral neuropathy in the human disease familial
amyloid polyneuropathy linked to transthyretin amyloidogenesis. I will
explain how delineating themolecular mechanism of transthyretin
aggregation linked to pathology led to a regulatory agency approved drug.
Since this is the first pharmacologic evidence supporting the amyloid
hypothesis, the notion that protein aggregation causes degeneration of the
heart and the nervous system, the last part of the seminar will focus on what
we have learned about the etiology of these diseases vis-à-vis a successful
clinical trial.
Tuesday, February 25, 3:30 pm
Room 1315 Chemistry